Efficacy of Tixagevimab-Cilgavimab as Immunoprophylaxis in Patients With Hematologic Cancer,JAMA Oncology

当前位置： X-MOL 学术 › JAMA Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy of Tixagevimab-Cilgavimab as Immunoprophylaxis in Patients With Hematologic Cancer
JAMA Oncology ( IF 28.4 ) Pub Date : 2024-01-25 , DOI: 10.1001/jamaoncol.2023.6446
Marco Salvini ₁ , Paolo Antonio Grossi _{1,

2} , Alessandro Cacioppo ₂ , Michele Merli ₃ , Giacomo Pellegrini ₁ , Marco Brociner ₁ , Francesco Passamonti _{3,

4}

Affiliation

This cohort study compares outcomes for patients with hematologic malignant tumors who prophylactically received tixagevimab-cilgavimab against SARS-CoV-2 with those who did not.

中文翻译：